Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Experimental Neurology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1016/j.expneurol.2013.11.001PMID 24220636
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Shared dysregulated pathways lead to Parkinson's disease and diabetes.

  2013cited by this paper
• The Type 2 Diabetes–Associated Gene Ide Is Required for Insulin Secretion and Suppression of α-Synuclein Levels in β-Cells

  2013cited by this paper
• Mechanisms of islet amyloidosis toxicity in type 2 diabetes

  2013cited by this paper
• New directions in ER stress-induced cell death

  2013cited by this paper
• A flash in the pan: Dissecting dynamic amyloid intermediates using fluorescence

  2013cited by this paper
• Endoplasmic Reticulum Stress-Associated Lipid Droplet Formation and Type II Diabetes

  2012cited by this paper
• Upregulated NLRP3 Inflammasome Activation in Patients With Type 2 Diabetes

  2012cited by this paper
• Targeting metabolic inflammation in Parkinson’s disease: Implications for prospective therapeutic strategies

  2012cited by this paper
• The NLRP3/ASC/Caspase‐1 axis regulates IL‐1β processing in neutrophils

  2012cited by this paper
• Nlrp3 Inflammasome Activation in Type 2 Diabetes: Is It Clinically Relevant?

  2012cited by this paper
• Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome–dependent processing of IL-1β

  2012cited by this paper
• Accumulation of Toxic α-Synuclein Oligomer within Endoplasmic Reticulum Occurs in α-Synucleinopathy In Vivo

  2012cited by this paper
• Cerebrovascular complications of diabetes: focus on stroke.

  2012cited by this paper
• Iptakalim Enhances Adult Mouse Hippocampal Neurogenesis Via Opening Kir6.1‐Composed K‐ATP Channels Expressed in Neural Stem Cells

  2012cited by this paper
• Endoplasmic reticulum stress and type 2 diabetes.

  2012cited by this paper
• Folding and misfolding of alpha-synuclein on membranes.

  2012cited by this paper
• Endoplasmic reticulum stress, obesity and diabetes.

  2012cited by this paper
• CHOP is a multifunctional transcription factor in the ER stress response.

  2012cited by this paper
• Role of ER Stress in Ventricular Contractile Dysfunction in Type 2 Diabetes

  2012cited by this paper
• Endoplasmic Reticulum Stress Is Important for the Manifestations of α-Synucleinopathy In Vivo

  2012cited by this paper
• Signalling by insulin and IGF receptors: supporting acts and new players.

  2011cited by this paper
• Diabetes and Risk of Parkinson’s Disease

  2011cited by this paper
• Diabetes and the Risk of Developing Parkinson’s Disease in Denmark

  2011cited by this paper
• What genetics tells us about the causes and mechanisms of Parkinson's disease.

  2011cited by this paper
• NLRP3 inflammasomes link inflammation and metabolic disease.

  2011cited by this paper
• Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes

  2010cited by this paper
• Progress in Parkinson's disease-where do we stand?

  2008cited by this paper
• Protocol for the MPTP mouse model of Parkinson's disease

  2007cited by this paper
• Metabolic Syndrome: Focus on Dyslipidemia

  2006cited by this paper
• The effect of diabetes and stroke at baseline and during follow-up on stroke mortality

  2006cited by this paper
• Diabetic neuropathies: a statement by the American Diabetes Association.

  2005cited by this paper
• Tyrosine-to-Cysteine Modification of Human α-Synuclein Enhances Protein Aggregation and Cellular Toxicity*

  2004cited by this paper
• Blood glucose and risk of cardiovascular disease in the Asia Pacific region.

  2004cited by this paper
• Dopaminergic neurons degenerate by apoptosis in Parkinson's disease

  1999cited by this paper
• Alpha-synuclein in Lewy bodies.

  1997cited by this paper
• α-Synuclein in Lewy bodies

  1997cited by this paper
• Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.

  1973cited by this paper

• Organelle stress in NLRP3 inflammasome: a central mediator of neurodegenerative diseases

  2026cites this paper
• Exploring glycolytic enzymes in disease: potential biomarkers and therapeutic targets in neurodegeneration, cancer and parasitic infections

  2025cites this paper
• From Diabetes to Degenerative Diseases: The Multifaceted Action of Metformin

  2025cites this paper
• Exploring the impact of metformin on the central nervous system and neurotransmission: A systematic review.

  2025cites this paper
• The Influence of Insulin Resistance and Type 2 Diabetes on Cognitive Decline and Dementia in Parkinson’s Disease: A Systematic Review

  2025influential citation
• Explainable machine learning-driven models for predicting Parkinson’s disease and its prognosis: obesity patterns associations and models development using NHANES 1999–2018 data

  2025cites this paper
• Comparison of Two MPTP Doses on Mouse Behaviors and Pathologies

  2025cites this paper
• Hyperglycemia Aggravates 6‐Hydroxydopamine‐Induced Neuronal Ferroptosis via SLC7A11‐Dependent Pathway in Diabetic PD Rat Model

  2025cites this paper
• Association of peripheral inflammatory cytokines with motor and non-motor symptoms in patients with Parkinson’s disease and type 2 diabetes mellitus

  2025cites this paper
• Exploring the link between estimated glucose disposal rate and Parkinson’s disease: cross-sectional and mortality analysis of NHANES 2003–2016

  2025cites this paper
• Parkinson's disease and brain insulin signaling: Mechanisms and potential role of GLP-1 mimetics.

  2025cites this paper
• GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease

  2024cites this paper
• Nanocarriers to mediate the pathways from diabetes toward Parkinson's disease

  2024cites this paper
• Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network

  2024cites this paper
• Protein tyrosine phosphatase receptor type O serves as a key regulator of insulin resistance-induced α-synuclein aggregation in Parkinson’s disease

  2024cites this paper
• Anti-diabetic drug use and reduced risk of Parkinson's disease: A community-based cohort study.

  2024cites this paper
• Frailty and Parkinson’s disease: the role of diabetes mellitus

  2024cites this paper
• Unraveling the Ties: Type 2 Diabetes and Parkinson's Disease - A Nano-Based Targeted Drug Delivery Approach.

  2024cites this paper
• The impact of diabetes mellitus on the development of psychiatric and neurological disorders

  2024cites this paper
• Mito-metformin protects against mitochondrial dysfunction and dopaminergic neuronal degeneration by activating upstream PKD1 signaling in cell culture and MitoPark animal models of Parkinson’s disease

  2024cites this paper
• NF‐κB/NLRP3 inflammasome axis and risk of Parkinson's disease in Type 2 diabetes mellitus: A narrative review and new perspective

  2023cites this paper
• Metabolic reprogramming of the inflammatory response in the nervous system: the crossover between inflammation and metabolism

  2023cites this paper
• A research update on Exendin-4 as a novel molecule against Parkinson's disease.

  2023cites this paper
• Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent

  2023cites this paper
• Melatonin-Driven NLRP3 Inflammation Inhibition Via Regulation of NF-κB Nucleocytoplasmic Transport: Implications for Postoperative Cognitive Dysfunction

  2023cites this paper
• Actions and Consequences of Insulin in the Striatum

  2023cites this paper
• Association of Cognitive Deficit with Glutamate and Insulin Signaling in a Rat Model of Parkinson’s Disease

  2023cites this paper
• The effect of progressive endurance training and extract of black winter truffle on proteins levels and expression of hippocampus α-synuclein and HSF1 in the healthy and diabetic rats

  2023influential citation
• Type 2 diabetes mellitus augments Parkinson's disease risk or the other way around: facts, challenges and future possibilities.

  2022cites this paper
• Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model

  2022cites this paper
• Incretin-based drugs as potential therapy for neurodegenerative diseases: Current status and perspectives.

  2022cites this paper
• Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease

  2022cites this paper
• Association between Parkinson’s Disease and Diabetes Mellitus: From Epidemiology, Pathophysiology and Prevention to Treatment

  2022cites this paper
• The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases

  2022cites this paper
• Oligomeropathies, inflammation and prion protein binding

  2022cites this paper
• Association Between Diabetes Medications and the Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis

  2021cites this paper
• The Role of the Effects of Autophagy on NLRP3 Inflammasome in Inflammatory Nervous System Diseases

  2021cites this paper
• Behavioral characterization in MPTP/p mouse model of Parkinson's disease.

  2021cites this paper
• Acute MPTP Treatment Impairs Dendritic Spine Density in the Mouse Hippocampus

  2021cites this paper
• Disruption of Endoplasmic Reticulum Proteostasis in Age-Related Nervous System Disorders.

  2021cites this paper
• Potential Crosstalk Between Parkinson's Disease and Energy Metabolism

  2021cites this paper
• L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease

  2021cites this paper
• Long-Term Hyperglycemia Induces α-Synuclein Aggregation and Dopaminergic Neuronal Loss in Parkinson's Disease Mouse Model

  2021cites this paper
• GLP-1 and GIP receptor agonists in the treatment of Parkinson’s disease: Translational systematic review and meta-analysis protocol of clinical and preclinical studies

  2021cites this paper
• The Impact of Obesity on Microglial Function: Immune, Metabolic and Endocrine Perspectives

  2021cites this paper
• A Mendelian randomization study of glycemic and anthropometric traits and Parkinson’s disease

  2020cites this paper
• The Association Between Type 2 Diabetes Mellitus and Parkinson’s Disease

  2020cites this paper
• Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease—Viewpoint

  2020cites this paper
• NLRP3 Inflammasomes in Parkinson's disease and their Regulation by Parkin.

  2020cites this paper
• Diabetes Causes Dysfunctional Dopamine Neurotransmission Favoring Nigrostriatal Degeneration in Mice

  2020cites this paper
• The NLRP3 inflammasome as a bridge between neuro-inflammation in metabolic and neurodegenerative diseases.

  2020cites this paper
• Tissue-specific features of microglial innate immune responses.

  2020cites this paper
• A bi-directional Mendelian randomization study of glycemic and anthropometric traits and 2 Parkinson’s disease 3

  2020cites this paper
• Thioredoxin-Interacting Protein (TXNIP) Regulates Parkin/PINK1-mediated Mitophagy in Dopaminergic Neurons Under High-glucose Conditions: Implications for Molecular Links Between Parkinson’s Disease and Diabetes

  2020cites this paper
• The Role of α-Synuclein Oligomers in Parkinson’s Disease

  2020cites this paper
• Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial

  2019cites this paper
• Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease

  2019influential citation
• Detrimental effect of type 2 diabetes mellitus in a large case series of Parkinson's disease.

  2019cites this paper
• PPARß/&dgr; agonist alleviates NLRP3 inflammasome‐mediated neuroinflammation in the MPTP mouse model of Parkinson's disease

  2019cites this paper
• The Relevance of Insulin Action in the Dopaminergic System

  2019cites this paper
• Emerging Neuroprotective effect of Metformin in Parkinson's disease: A Molecular crosstalk.

  2019cites this paper
• Analysis of the Relationship between Type II Diabetes Mellitus and Parkinson's Disease: A Systematic Review

  2019cites this paper
• Endoplasmic reticulum stress and NLRP3 inflammasome: Crosstalk in cardiovascular and metabolic disorders

  2019cites this paper
• Long-term liraglutide ameliorates nigrostriatal impairment via regulating AMPK/PGC-1a signaling in diabetic mice.

  2019cites this paper
• Blocking meningeal lymphatic drainage aggravates Parkinson’s disease-like pathology in mice overexpressing mutated α-synuclein

  2019cites this paper
• Submicron Crystals of the Parkinson’s Disease Substantia nigra: Calcium Oxalate, Titanium Dioxide and Iron Oxide

  2019cites this paper
• 1 Drug repurposing in Parkinson ’ s disease

  2018cites this paper
• Glial loss of the metallo β-lactamase domain containing protein, SWIP-10, induces age- and glutamate-signaling dependent, dopamine neuron degeneration

  2018cites this paper
• Leptin and ghrelin: Sewing metabolism onto neurodegeneration

  2018cites this paper
• The Therapeutic Potential of Metformin in Neurodegenerative Diseases

  2018cites this paper
• Drug Repurposing in Parkinson’s Disease

  2018cites this paper
• Diabète de type 2 et maladies neurodégénératives : un domaine émergent

  2017cites this paper
• High Glucose Enhances Neurotoxicity and Inflammatory Cytokine Secretion by Stimulated Human Astrocytes.

  2017cites this paper
• Caspase-1 Deficiency Alleviates Dopaminergic Neuronal Death via Inhibiting Caspase-7/AIF Pathway in MPTP/p Mouse Model of Parkinson’s Disease

  2017cites this paper
• Accumulation of α-Synuclein in Cerebellar Purkinje Cells of Diabetic Rats and Its Potential Relationship with Inflammation and Oxidative Stress Markers

  2017cites this paper
• Melatonin as an Anti-Inflammatory Agent Modulating Inflammasome Activation

  2017cites this paper
• Inflammasomes and type 2 diabetes: An updated systematic review.

  2017cites this paper
• Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease.

  2017cites this paper
• Neuroprotective properties of incretin mimetics in brain ischemia and neurodegenerative diseases

  2017cites this paper
• Role of metabolism in neurodegenerative disorders.

  2016cites this paper
• Insulin resistance and Parkinson's disease: A new target for disease modification?

  2016cites this paper
• A Role for the NLR Family Members NLRC4 And NLRP3 in Astrocytic Inflammasome Activation and Astrogliosis

  2016cites this paper
• Inflammasome-mediated activation of microglia : Tissue-specific features of innate immunity

  2016cites this paper
• Translational drug discovery approaches targeting the PKD1 signaling in Parkinson's disease

  2016cites this paper
• Systematic literature review on Parkinson's disease and Childhood Leukaemia and mode of actions for pesticides

  2016cites this paper
• The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action.

  2016influential citation
• Middle-Aged Diabetic Females and Males Present Distinct Susceptibility to Alzheimer Disease-like Pathology

  2016cites this paper
• Mitochondrial control of cell bioenergetics in Parkinson's disease.

  2016cites this paper
• Degeneration of Dopaminergic Neurons Due to Metabolic Alterations and Parkinson’s Disease

  2016cites this paper
• Integrative transcriptomic meta-analysis of Parkinson’s disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson’s disease

  2016cites this paper
• Caspase-1 inhibition attenuates activation of BV2 microglia induced by LPS-treated RAW264.7 macrophages

  2016cites this paper
• Melatonin attenuated early brain injury induced by subarachnoid hemorrhage via regulating NLRP3 inflammasome and apoptosis signaling

  2016cites this paper
• Microglia-Mediated Neuroinflammation and Neurotrophic Factor-Induced Protection in the MPTP Mouse Model of Parkinson’s Disease-Lessons from Transgenic Mice

  2016cites this paper
• Enrichment of risk SNPs in regulatory regions implicate diverse tissues in Parkinson’s disease etiology

  2016cites this paper
• Increased susceptibility to metabolic dysregulation in a mouse model of Alzheimer's disease is associated with impaired hypothalamic insulin signaling and elevated BCAA levels

  2016cites this paper
• Metformin Prevents Dopaminergic Neuron Death in MPTP/P-Induced Mouse Model of Parkinson’s Disease via Autophagy and Mitochondrial ROS Clearance

  2016cites this paper
• Control of Autophagy in Parkinson’s Disease

  2015cites this paper
• Longevity Pathways (mTOR, SIRT, Insulin/IGF-1) as Key Modulatory Targets on Aging and Neurodegeneration.

  2015cites this paper
• Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide.

  2015cites this paper
• Dysregulation of parkin in the substantia nigra of db/db and high-fat diet mice.

  2015influential citation